Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology

How Is CIDP Diagnosed and How Long Does Diagnosis Take?

At a Glance

CIDP is diagnosed by combining a symptom history, neurologic examination, nerve conduction studies and EMG, and tests for other causes. Symptoms must show a progressive or relapsing pattern for at least eight weeks, and diagnosis averages five to seven months from symptom onset.

Urgent Care Warning: If you experience rapidly worsening weakness, new difficulty breathing or swallowing, inability to stand or walk, or repeated falls, seek emergency medical care immediately. Do not wait for an appointment. These can be signs of acute conditions like Guillain-Barré syndrome (GBS) or other neurological emergencies.

Diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP) is a careful, multi-step process that combines your medical history, a physical exam, and specialized nerve tests. Because there is no single blood test that definitively proves you have CIDP, reaching a diagnosis can take time. While some people are diagnosed promptly, studies show that the average time from symptom onset to diagnosis is between five and seven months [1][2]. You do not need to wait months to seek care; rather, this timeline reflects the time it often takes to observe the disease’s progression and run comprehensive tests to screen for conditions that mimic CIDP [3].

Your First Neurology Visit

At your initial visit, your neurologist will focus on gathering a detailed history of your symptoms and conducting a thorough neurologic exam [4]. They will ask how your weakness and sensory changes affect your daily life, such as your ability to walk, climb stairs, or grip objects [5][6]. During the physical exam, the doctor often looks for symmetric weakness (affecting both sides of your body equally), loss of sensation, and reduced or absent reflexes [7].

However, not everyone has these classic signs. There are CIDP variants that involve uneven (asymmetric) weakness, affect only sensory or motor nerves, or leave your reflexes intact. Having normal reflexes or asymmetric symptoms does not rule out CIDP, but it may require a neuromuscular specialist to interpret [8].

The 8-Week Timeline

A key part of diagnosing CIDP is the element of time. The disease is defined as “chronic,” meaning the clinical criteria require symptoms to have steadily progressed or relapsed for at least eight weeks [7]. In the very early stages, acute-onset CIDP can look identical to Guillain-Barré syndrome (GBS), which is a sudden condition [9].

If you have already experienced eight weeks of worsening symptoms before your first appointment, your doctor can use your history to meet this diagnostic criterion immediately. If your symptoms are newer, your care team will closely monitor your complete clinical course alongside your test results to distinguish CIDP from acute nerve conditions [10].

Core Diagnostic Tests

CIDP involves the immune system attacking the myelin (the protective coating around your nerves). To confirm this, doctors use tests that look for demyelination (damage to the myelin) [3].

  • Nerve Conduction Studies (NCS) and Needle EMG: These are two distinct but complementary tests used to evaluate your nerves and muscles [3]. NCS uses small electrical pulses on your skin to measure how fast and strong the signals travel through your nerves. The doctor looks for slowed conduction, delayed signals, or “conduction block” (where the electrical signal drops off). Needle EMG involves placing a fine needle into the muscle to assess its electrical activity. Neither test alone proves CIDP; a specialist must interpret these complex findings against formal diagnostic criteria to rule out other causes [11].
  • Laboratory Screening Tests: Blood tests are individualized to screen for other diseases that mimic CIDP. Your doctor may check for diabetes, vitamin deficiencies, thyroid disease, HIV, and monoclonal gammopathy (abnormal proteins in the blood) [12][13]. Genetic neuropathies cannot be ruled out by routine blood tests; they require a review of your family history and specific genetic testing [3].

Supportive Studies

If your nerve tests do not provide a definitive answer, your doctor may order additional tests to gather supportive evidence. These tests cannot prove CIDP on their own, but they help build a diagnostic case [8].

  • Lumbar Puncture (Spinal Tap): This is used to check your spinal fluid for elevated protein levels without a high white blood cell count. While common in CIDP, elevated protein is not specific and can be caused by age or diabetes. If your nerve tests already clearly show CIDP, a lumbar puncture is not always required [14][15].
  • Nerve Ultrasound or MRI: These imaging tools can look for enlarged or inflamed nerves [8][16].
  • Nerve Biopsy: This is a rare and invasive surgical procedure that removes a tiny piece of nerve for examination under a microscope. It can cause permanent numbness and is generally reserved only for highly complex diagnostic dilemmas [8].

Why Diagnosis Takes Time and When to See a Specialist

It is normal for diagnostic uncertainty to cause stress. Early symptoms can be subtle, and atypical forms of the disease can easily be mistaken for other types of neuropathy [17][1]. Because nerve tests require careful interpretation, sometimes the results are borderline, leading to a risk of misdiagnosis or overdiagnosis [18][19].

Do not wait for treatments to fail before seeking a second opinion. If your symptoms are unusual, if your electrodiagnostic tests are borderline, or if your diagnosis remains uncertain, it is highly recommended to seek an early referral to a neuromuscular specialist or a CIDP center of excellence [5][20].

How to Prepare for Your Appointments

To help your care team reach an accurate diagnosis as quickly as possible, come prepared to your visits:

  • Symptom Timeline: Write down exactly when your symptoms started and whether they have progressed, fluctuated, or relapsed over time [9].
  • Medical Records: Bring copies of any previous nerve conduction studies (EMG/NCS), spinal fluid tests, or blood work [5][21].
  • Health History & Medications: Provide a complete list of your current medications and your full medical history, especially if you have a history of diabetes or autoimmune conditions [22][23].
  • Family History: Mention if any blood relatives have a history of neuropathy, as this can help rule out genetic causes [24].

Common questions in this guide

What tests are used to diagnose CIDP?
Doctors combine your symptom history, a neurological examination, nerve conduction studies, and needle electromyography (EMG) to evaluate CIDP. Blood tests help look for other conditions that can cause similar nerve symptoms, and additional studies may be used when the diagnosis is unclear. No single blood test confirms CIDP.
How long does it usually take to get a CIDP diagnosis?
The average time from symptom onset to diagnosis is about five to seven months, although some people are diagnosed sooner and others take longer. CIDP is defined by symptoms that steadily worsen or relapse for at least eight weeks, and clinicians may need time to observe the pattern and rule out other conditions.
Why is an eight-week timeline important for CIDP?
CIDP is considered chronic when weakness or other nerve symptoms progress or relapse for at least eight weeks. Very early CIDP can resemble Guillain-Barré syndrome, which develops suddenly, so doctors may monitor your course and review tests before reaching a firm diagnosis.
What do EMG and nerve conduction studies show in CIDP?
Nerve conduction studies measure how quickly and strongly electrical signals travel through nerves, while a needle EMG measures electrical activity in muscles. Findings such as slowed signals, delayed responses, or a drop in signal along a nerve may support myelin damage, but a specialist must interpret the results alongside other clinical information.
What other conditions are checked when CIDP is suspected?
Blood tests may check for diabetes, vitamin deficiencies, thyroid disease, HIV, and abnormal blood proteins. A family history review and, when appropriate, genetic testing can help identify inherited neuropathies, which routine blood tests do not rule out.
When should I see a neuromuscular specialist for possible CIDP?
An early specialist opinion can be helpful when symptoms are unusual, nerve-test results are borderline, or the diagnosis remains uncertain. A neuromuscular specialist can review the findings against formal CIDP criteria and help decide whether more testing is needed.
What should I do if my weakness gets worse while I am being evaluated for CIDP?
Seek emergency medical care immediately if weakness is rapidly worsening, you develop new difficulty breathing or swallowing, you cannot stand or walk, or you have repeated falls. Do not wait for a routine appointment because these symptoms can signal an acute neurological emergency.

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Real-World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape.

    Querol L, Rinaldi S, Borsi A, et al.

    Journal of the peripheral nervous system : JPNS 2025; (30(3)):e70047 doi:10.1111/jns.70047.

    PMID: 40826893
  2. 2

    The journey to diagnosis for patients with CIDP: results from a real-world international survey.

    Arvin-Berod C, Brackx F, Van de Veire L, et al.

    Frontiers in neurology 2025; (16()):1748903 doi:10.3389/fneur.2025.1748903.

    PMID: 41716962
  3. 3

    History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Dyck PJB, Tracy JA

    Mayo Clinic proceedings 2018; (93(6)):777-793 doi:10.1016/j.mayocp.2018.03.026.

    PMID: 29866282
  4. 4

    [Immune-mediated neuropathies].

    Stoll G, Reiners K

    Der Nervenarzt 2016; (87(8)):887-98 doi:10.1007/s00115-016-0164-3.

    PMID: 27474733
  5. 5

    Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach.

    Stino AM, Naddaf E, Dyck PJ, Dyck PJB

    Muscle & nerve 2021; (63(2)):157-169 doi:10.1002/mus.27046.

    PMID: 32914902
  6. 6

    Evaluating Grasp Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Using Dynamometers: A Comprehensive Review.

    Tsoumanis P, Chatzoglou T, Smyris TI, et al.

    Journal of clinical medicine research 2025; (17(3)):136-144 doi:10.14740/jocmr6179.

    PMID: 40115839
  7. 7

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Its Variants.

    Gwathmey K

    Continuum (Minneapolis, Minn.) 2020; (26(5)):1205-1223 doi:10.1212/CON.0000000000000907.

    PMID: 33002999
  8. 8

    Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy.

    Lewis RA, van Doorn PA, Sommer C

    Journal of the neurological sciences 2022; (443()):120478 doi:10.1016/j.jns.2022.120478.

    PMID: 36368137
  9. 9

    Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerves and respiratory tract involvement: A case report.

    Mansour M, Ouerdiene A, Bedoui I, et al.

    Clinical case reports 2020; (8(11)):2199-2203 doi:10.1002/ccr3.3087.

    PMID: 33235757
  10. 10

    Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients.

    Alessandro L, Pastor Rueda JM, Wilken M, et al.

    Journal of the peripheral nervous system : JPNS 2018; (23(3)):154-158 doi:10.1111/jns.12266.

    PMID: 29603827
  11. 11

    Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy.

    Eftimov F, Lucke IM, Querol LA, et al.

    Brain : a journal of neurology 2020; (143(11)):3214-3224 doi:10.1093/brain/awaa265.

    PMID: 33155018
  12. 12

    [Pitfalls for Diagnosis of Polyneuropathy by Nerve Conduction Study].

    Misawa S

    Brain and nerve = Shinkei kenkyu no shinpo 2020; (72(4)):417-423 doi:10.11477/mf.1416201540.

    PMID: 32284466
  13. 13

    Charcot-Marie-Tooth type 4 C misdiagnosed as CIDP: electrodiagnostic pitfalls and genetic confirmation.

    Okhovat AA, Shahriyari H, Ghasemi A, et al.

    Neurogenetics 2026; (27(1)).

    PMID: 42377577
  14. 14

    The Misdiagnosis of CIDP: A Review.

    Allen JA

    Neurology and therapy 2020; (9(1)):43-54 doi:10.1007/s40120-020-00184-6.

    PMID: 32219701
  15. 15

    Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis.

    Breiner A, Bourque PR, Allen JA

    Muscle & nerve 2019; (60(2)):180-183 doi:10.1002/mus.26488.

    PMID: 30989684
  16. 16

    Neuropathy associated with immunoglobulin M monoclonal gammopathy: A combined sonographic and nerve conduction study.

    Goedee HS, Notermans NC, Visser LH, et al.

    Muscle & nerve 2019; (60(3)):263-270 doi:10.1002/mus.26626.

    PMID: 31269243
  17. 17

    Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.

    Chaudhary UJ, Rajabally YA

    Journal of neurology 2021; (268(4)):1366-1373 doi:10.1007/s00415-020-10287-7.

    PMID: 33170339
  18. 18

    CIDP diagnostic pitfalls and perception of treatment benefit.

    Allen JA, Lewis RA

    Neurology 2015; (85(6)):498-504 doi:10.1212/WNL.0000000000001833.

    PMID: 26180143
  19. 19

    Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis.

    Allen JA, Ney J, Lewis RA

    Muscle & nerve 2018; (57(4)):542-549 doi:10.1002/mus.25997.

    PMID: 29053880
  20. 20

    Diagnosis of chronic inflammatory demyelinating polyneuropathy.

    Allen JA, Lewis RA

    Muscle & nerve 2022; (66(5)):545-551 doi:10.1002/mus.27708.

    PMID: 36259623
  21. 21

    Chronic Immune-Mediated Polyneuropathies.

    Cox SZ, Gwathmey KG

    Clinics in geriatric medicine 2021; (37(2)):327-345 doi:10.1016/j.cger.2021.01.006.

    PMID: 33858614
  22. 22

    Infliximab induced chronic inflammatory demyelinating polyneuropathy: a case report.

    Karantali E, Katsikaki G, Chatzikonstantinou S, Papagiannopoulos S

    Hippokratia 2019; (23(4)):179-180.

    PMID: 32742170
  23. 23

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management.

    Chen Y, Tang X

    Frontiers in immunology 2022; (13()):890142 doi:10.3389/fimmu.2022.890142.

    PMID: 35860284
  24. 24

    Hereditary Neuropathy with Liability to Pressure Palsies Mimicking a Chronic Inflammatory Demyelinating Polyneuropathy Variant: A Case Report Highlighting Diagnostic Challenges.

    Yamamoto M, Hatanaka Y, Kaida K

    Internal medicine (Tokyo, Japan) 2026; (65(9)):1302-1306 doi:10.2169/internalmedicine.5771-25.

    PMID: 41062314

This page explains the CIDP diagnostic process for informational purposes only and does not constitute medical advice. A neurologist or neuromuscular specialist should interpret your results; seek urgent care for rapidly worsening weakness or breathing or swallowing problems.